These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 28445987

  • 1. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
    Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.
    Oncotarget; 2017 Apr 11; 8(15):25395-25417. PubMed ID: 28445987
    [Abstract] [Full Text] [Related]

  • 2. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.
    Proc Natl Acad Sci U S A; 2017 Jul 18; 114(29):E5930-E5939. PubMed ID: 28684402
    [Abstract] [Full Text] [Related]

  • 3. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M, Wu L, Zhang K, Wang H, Wu S, O'Connell D, Gao T, Zhong H, Yang Y.
    Cell Signal; 2018 Jan 18; 42():30-43. PubMed ID: 28982601
    [Abstract] [Full Text] [Related]

  • 4. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X, Qu H, Dong Y, Wang G, Zhen Y, Zhang L.
    Cancer Biomark; 2018 Jan 18; 23(1):67-77. PubMed ID: 30010109
    [Abstract] [Full Text] [Related]

  • 5. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
    Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R.
    J Invest Dermatol; 2013 Aug 18; 133(8):2041-9. PubMed ID: 23344460
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MicroRNA-21 regulates the ERK/NF-κB signaling pathway to affect the proliferation, migration, and apoptosis of human melanoma A375 cells by targeting SPRY1, PDCD4, and PTEN.
    Mao XH, Chen M, Wang Y, Cui PG, Liu SB, Xu ZY.
    Mol Carcinog; 2017 Mar 18; 56(3):886-894. PubMed ID: 27533779
    [Abstract] [Full Text] [Related]

  • 12. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
    Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixidó J.
    Cancer Res; 2018 Feb 15; 78(4):1017-1030. PubMed ID: 29229605
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 14. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A, Cohen MS.
    Expert Opin Drug Discov; 2016 Sep 10; 11(9):907-16. PubMed ID: 27327499
    [Abstract] [Full Text] [Related]

  • 15. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C, Yang L, Yang M, Li Y, Shen G, Tu Y, Tao J.
    Oncotarget; 2016 Aug 16; 7(33):53558-53570. PubMed ID: 27448964
    [Abstract] [Full Text] [Related]

  • 16. Exosomal miR-19a derived from melanoma cell promotes the vemurafenib resistance of malignant melanoma through directly targeting LRIG1 to reactivate AKT and MAPK pathway.
    Luan W, Lu X, Peng H, Shen X, Rao M, Ruan H.
    Pathol Res Pract; 2024 Aug 16; 260():155410. PubMed ID: 38955119
    [Abstract] [Full Text] [Related]

  • 17. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
    Pedini F, De Luca G, Felicetti F, Puglisi R, Boe A, Arasi MB, Fratini F, Mattia G, Spada M, Caporali S, Biffoni M, Giuliani A, Carè A, Felli N.
    Mol Oncol; 2019 Sep 16; 13(9):1836-1854. PubMed ID: 31115969
    [Abstract] [Full Text] [Related]

  • 18. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
    Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.
    Oncotarget; 2015 Jul 10; 6(19):17753-63. PubMed ID: 25980496
    [Abstract] [Full Text] [Related]

  • 19. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.
    EBioMedicine; 2016 Jun 10; 8():132-149. PubMed ID: 27428425
    [Abstract] [Full Text] [Related]

  • 20. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
    Pucciarelli D, Lengger N, Takáčová M, Csaderova L, Bartosova M, Breiteneder H, Pastorekova S, Hafner C.
    Mol Med Rep; 2016 Apr 10; 13(4):3281-8. PubMed ID: 26936534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.